drugset / Trial / NCT07617493
Evaluation of ICP-B208 in Patients With Advanced Solid Tumors
NaSequentialOpen-labelTreatment
Summary
To evaluate the safety, tolerability, efficacy and pharmacokinetic characteristics of ICP-B208 in the trial participants of unresectable advanced or metastatic solid tumors
Timeline
- Start
- 2026-07-03
- Primary completion
- 2030-12
- Completion
- 2031-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ICP-B208 | Unknown | — | Intravenous |